Cardinals outfielder Lars Nootbaar was among the players that St. Louis brass announced underwent surgery earlier this month, as he went under the knife on October 7 to shave down Haglund’s deformities on both heels. At the time, Nootbaar’s timetable for a return to action was unclear, but today president of baseball operations Chaim Bloom revealed to Matt Pauley of KMOX Sports in a radio interview that Opening Day is neither entirely off the table nor entirely guaranteed for Nootbaar following his surgery. Bloom adds that they don’t intend to rush the rehab process in order to get him back on time for the start of the season, but that if he were to miss time to open the season the absence would be limited.
As far as timelines for offseason surgeries go, Nootbaar’s doesn’t seem to worrisome. It would naturally be less than ideal if he were to miss time to open the 2026 campaign but, with the Cardinals headed into a likely rebuilding phase as it is, the handful of games Nootbaar is at risk of missing at the start of the season are unlikely to be the difference in the club’s postseason chances next year. Given that Nootbaar is coming off a career-worst season where he hit just .234/.325/.361 (96 wRC+) following three consecutive seasons where he posted a wRC+ of 114 or higher, a few extra days missed at the start of the season would be well worth it for the Cardinals if it means that Nootbaar puts his best foot forward as he tries to return to the more robust offensive form he had flashed in previous seasons.
The 28-year-old is under team control with St. Louis for two more seasons before he’s slated to reach free agency during the 2027-28 offseason. For a Cardinals team that might not return to contention until Nootbaar is already a free agent, he’s certainly a logical trade candidate. Today’s news about Nootbaar’s uncertain status for Opening Day might make a trade slightly less likely to come together, but the impact on his market is likely at least relatively negligible.
After all, clubs already knew Nootbaar would be rehabbing from surgery this offseason and his dip in performance last year might have made the Cardinals hesitant to deal him before giving him the opportunity to rebound and improve his stock following his recent surgery. St. Louis has little incentive to risk selling low on Nootbaar given that he could theoretically be dealt at the 2026 trade deadline and still be available to an interested club for two pennant races and eligible for a Qualifying Offer following the 2027 season, should the QO still exist after the next round of collective bargaining negotiations next winter.
Looking at the Cardinals’ current depth chart, the possibility of losing Nootbaar for a few games to open the year shouldn’t be too much of a problem if the rest of the team’s positional corps remains healthy. Jordan Walker, Victor Scott II, Alec Burleson, and Brendan Donovan could all see time in the outfield next year, to say nothing of potential depth options like Nathan Church and Michael Siani behind that primary group. Donovan is generally viewed as more likely to spend time on the infield next year, especially if the club manages to trade Nolan Arenado this winter, but Nolan Gorman and Thomas Saggesse should be able to fill in for Donovan when he plays the outfield.